Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: A systematic review

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1395-1404

  Marks, W H ^a   Ilsley, J N ^b   Dharnidharka, V R ^c  

^a SWEDISH MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c University of Florida and UF Health Shands Children s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; INOLIMOMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ARTICLE; CARDIAC GRAFT REJECTION; EMBASE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTILYMPHOCYTE SERUM; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS;

EID: 79959390947     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.036     Document Type: Article

References (54)

1. Epstein-Barr virus and lymphoproliferative disorders after transplantation Am J Transplant 4 Suppl 10 2004 59
2. P. Andreone, A. Gramenzi, and S. Lorenzini Posttransplantation lymphoproliferative disorders Arch Intern Med 163 2003 1997
3. A.L. Taylor, R. Marcus, and J.A. Bradley Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation Crit Rev Oncol Hematol 56 2005 155
4. Post-transplant lymphoproliferative disorders 2010 Springer
5. W.S. Cherikh, H.M. Kauffman, and M.A. McBride Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation Transplantation 76 2003 1289
6. V.R. Dharnidharka, A.H. Tejani, P.L. Ho, and W.E. Harmon Post-transplant lymphoproliferative disorder in the United States: young caucasian males are at highest risk Am J Transplant 2 2002 993
7. V.R. Dharnidharka, and G. Stevens Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation Pediatr Transplant 9 2005 622
8. G. Opelz, and B. Dhler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222
9. M.J. Aull, J.F. Buell, and J. Trofe Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry Transplantation 78 2004 1676
10. L.J. Swinnen, M.R. Costanzo-Nordin, and S.G. Fisher Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients N Engl J Med 323 1990 1723
11. S. Caillard, V. Dharnidharka, and L. Agodoa Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression Transplantation 80 2005 1233
12. S.M. Cockfield Identifying the patient at risk for post-transplant lymphoproliferative disorder Transpl Infect Dis 3 2001 70
13. S.A. Birkeland, and S. Hamilton-Dutoit Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 76 2003 984
14. V.R. Dharnidharka, and C.E. Araya Post-transplant lymphoproliferative disease Pediatr Nephrol 24 2009 731
15. D.C. Brennan, J.A. Daller, and K.D. Lake Rabbit antithymocyte globulin versus basiliximab in renal transplantation N Engl J Med 355 2006 1967
16. D.C. Brennan, K. Flavin, and J.A. Lowell A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients Transplantation 67 1999 1011
17. N. Bonaros, D. Dunkler, and A. Kocher Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation J Heart Lung Transplant 25 2006 1154
18. US Department of Health and Human Services Immunosuppression use by organ in 2006 and 2007 In: 2008 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant data 19982007 http://www.ustransplant.org/annual-reports/current/ 109a-dh.htm Accessed December 21, 2009
19. K.L. Hardinger, S. Rhee, and P. Buchanan A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results Transplantation 86 2008 947
20. M.G. Crespo-Leiro, L. Alonso-Pulpón, and J.M. Arizón Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish PostHeart Transplant Tumour Registry J Heart Lung Transplant 26 2007 1105
21. R.T. Bustami, A.O. Ojo, and R.A. Wolfe Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients Am J Transplant 4 2004 87
22. R.J. Faull, P. Hollett, and S.P. McDonald Lymphoproliferative disease after renal transplantation in Australia and New Zealand Transplantation 80 2005 193
23. G. Opelz, C. Naujokat, and V. Daniel Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients Transplantation 81 2006 1227
24. A.D. Kirk, W.S. Cherikh, and M. Ring Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant 7 2007 2619
25. I. El-Hamamsy, L.M. Stevens, and M. Carrier Incidence and prognosis of cancer following heart transplantation using RATG induction therapy Transpl Int 18 2005 1280
26. D.C. Brennan, and M.A. Schnitzler Long-term results of rabbit antithymocyte globulin and basiliximab induction N Engl J Med 359 2008 1736
27. D.P. Funch, A.M. Walker, G. Schneider, N.J. Ziyadeh, and M.D. Pescovitz Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients Am J Transplant 5 2005 2894
28. A. Al Najjar, I. Etienne, and P. le Pogamp Long-term results of monoclonal antiIL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation Transplant Proc 38 2006 2298
29. J.W. Alexander, H.R. Goodman, and M. Cardi Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation Transpl Int 19 2006 295
30. S. Beaudreuil, A. Durrbach, and J. Noury Long-term results (10 years) of a prospective trial comparing Lo-Tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation Transpl Int 19 2006 814
31. S.A. Birkeland Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients Transplantation 71 2001 1089
32. L. Esposito, N. Kamar, D. Durand, and L. Rostaing Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety Transplant Proc 37 2005 892
33. J.M. Grinyo, S. Gil-Vernet, and J.M. Cruzado Calcineurin inhibitorfree immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years Transpl Int 16 2003 820
34. K.L. Hardinger, M.A. Schnitzler, and M.J. Koch Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience Transplantation 81 2006 1285
35. A.J. Matas, R. Kandaswamy, and K.J. Gillingham Prednisone-free maintenance immunosuppressiona 5-year experience Am J Transplant 5 2005 2473
36. U. Ott, M. Busch, and T. Steiner Renal retransplantation: a retrospective monocentric study Transplant Proc 40 2008 1345
37. L.S. de Santo, G. Romano, and C. Mastroianni Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy Transplant Proc 37 2005 2684
38. I.M. Hamour, H.S. Lyster, and M.M. Burke Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients Transplantation 83 2007 570
39. A.O. Zuckermann, M. Grimm, and M. Czerny Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines Transplantation 69 2000 1890
40. T. Soliman, H. Hetz, and C. Burghuber Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation Liver Transpl 13 2007 1039
41. D. Ducloux, A. Kazory, and B. Challier Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study Transplantation 77 2004 1029
42. M. Rinaldi, C. Pellegrini, and A.M. D'Armini Neoplastic disease after heart transplantation: single center experience Eur J Cardiothorac Surg 19 2001 696
43. M. Carrier, M. White, and L.P. Perrault A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation J Heart Lung Transplant 18 1999 1218
44. US Department of Health and Human Services Recipient de novo post transplant lymphoproliferative disorders (PTLD), 1998 to 2007, by transplant type In: 2008 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant data 19982007 http://www.ustransplant.org/annual-reports/current/1404-tum.htm Accessed December 21, 2009
45. V.R. Dharnidharka Post-transplant lymphoproliferative disease: association with induction therapy? Drugs 66 2006 429
46. K.A. Herzig, H.G. Juffs, and D. Norris A single-centre experience of post-renal transplant lymphoproliferative disorder Transpl Int 16 2003 529
47. R.B. Stevens, D.F. Mercer, and W.J. Grant Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report Transplantation 85 2008 1391
48. B. Charpentier, L. Rostaing, and F. Berthoux A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients Transplantation 75 2003 844
49. G. Mourad, V. Garrigue, and J.P. Squifflet Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression Transplantation 72 2001 1050
50. A. Humar, and M. Michaels American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation Am J Transplant 6 2006 262
51. KDIGO clinical practice guideline for the care of kidney transplant recipients Am J Transplant 9 Suppl 3 2009 S1
52. S.A. Birkeland, H.K. Andersen, and S.J. Hamilton-Dutoit Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol Transplantation 67 1999 1209
53. I.A. Darenkov, M.A. Marcarelli, and G.P. Basadonna Reduced incidence of Epstein-Barr virusassociated posttransplant lymphoproliferative disorder using preemptive antiviral therapy Transplantation 64 1997 848
54. M.D. Pescovitz Benefits of cytomegalovirus prophylaxis in solid organ transplantation Transplantation 2 2 Suppl 2006 S4